Cellectricon

Cellectricon is a collaborative services provider dedicated to advance drug discovery and research in the areas of chronic pain and neurodegenerative disease. We are a team of highly experienced neurobiologists, stem cell researchers and engineers, with a proven track record of developing innovative in vitro assays of enhanced translational value for our Clients. We always aim for long-term partnerships with our Clients, based on mutual trust and commitment.

What sets us apart from the competition is our proprietary discovery platform. In collaboration with leading academic institutions and pharmaceutical companies, we have over the last 10 year’s continuously refined and validated our patented core technology to a point where we feel we can establish testing paradigms that are impossible to recreate with other methods. We excel at the generation of high quality primary neuronal cell cultures from e.g. peripheral ganglia, spinal cord and brain, as well as from human iPSC-derived neurons. Our assays fill the gap between less complex model systems, such as high throughput screening in over-expressing cell lines and in vivo animal models, and are enabling our Clients to better prioritize which molecules to advance into the Clinic.

Our discovery platform enables high capacity testing of changes in excitability and synaptic communication in native and iPSC-derived neurons. The capacity can be applied not only for screening of large number of compounds but also to efficiently identify optimal assay parameters and thereby maximizing translatability. Further, the functional assays can be coupled to downstream HCA assays to provide complementary data on cellular and network morphology.
Our research services include:
• Exploratory proof of concept studies.
• Customized assay development.
• Phenotypic and target-based screening.
• Genomic screening for target ID and target deconvolution efforts.
• Improved testing methodologies in lead optimization.
• Preclinical compound validation.

Based in Sweden, Cellectricon AB is a privately held company. The main shareholders are Ägir Invest, Dunross & Co., together with employees and seed investors.